Synthesis and biological evaluation of bis(methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors

Arch Pharm (Weinheim). 2005 Oct;338(10):502-5. doi: 10.1002/ardp.200500126.

Abstract

A series of 7,8-bis(methoxymethyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines were prepared and evaluated for their inhibition of phosphorylation of the isolated epidermal growth factor receptor (EGFR) enzyme and for their growth inhibition of the A431 cell line. Among them, compound 3c having a 3-iodophenyl ring was most potent (IC(50) = 1.66 nM) against the isolated EGFR enzyme and also showed meaningful potency (GI(50) = 1.99 microM) against the A431 cell line, although less than PD153035 (GI(50) = 1.03 microM). However, compound 3e as the exact rigidified analogue of Erlotinib (Tarceva) was inferior to the original compound when compared to its reported data.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Proliferation
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / pharmacology
  • ErbB Receptors / antagonists & inhibitors*
  • HCT116 Cells
  • Humans
  • Inhibitory Concentration 50
  • Quinazolines / chemical synthesis*
  • Quinazolines / pharmacology
  • Structure-Activity Relationship

Substances

  • Enzyme Inhibitors
  • Quinazolines
  • ErbB Receptors